Skip to main content

Advertisement

SpringerLink
Log in

Effect of Beta-Blockers on Bone Mineral Density, Bone Turnover Markers and Fractures: A Clinical Review

  • Hypertension and bone
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

The increased sympathetic nervous activity causes bone loss, via an increase in osteoclastic bone resorption and a decrease in osteoblastic bone formation, suggesting an important regulating role for the SNS in bone metabolism. Such findings may indicate that pharmacological beta-blockade could be a target to increase bone mass and reduce the risk of fractures. This review summarized the impact of beta-blockers on bone mineral density, bone turnover markers and fracture risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP. Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int. 2009;20:197–207.

    Article  CAS  PubMed  Google Scholar 

  2. Hernández JL, Olmos JM, Romaña G, Llorca J, Martínez J, Castillo J, de Juan J, Pérez-Pajares I, Ruiz S, González-Macías J. Influence of vitamin D status on the effect of statins on bone mineral density and bone turnover markers in postmenopausal women. J Clin Endocrinol Metab. 2014;99:3304–9.

    Article  PubMed  Google Scholar 

  3. Olmos JM, Hernández JL, Martínez J, Castillo J, Valero C, Pérez Pajares I, Nan D, González-Macías J. Bone turnover markers and bone mineral density in hypertensive postmenopausal women on treatment. Maturitas. 2010;65:396–402.

    Article  PubMed  Google Scholar 

  4. Togari A, Arai M, Kondo A. The role of the sympathetic nervous system in controlling bone metabolism. Expert Opin Ther Targets. 2005;9:931–40.

    Article  CAS  PubMed  Google Scholar 

  5. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305–17.

    Article  CAS  PubMed  Google Scholar 

  6. Baek K, Bloomfield SA. Blocking β-adrenergic signaling attenuates reductions in circulating leptin, cancellous bone mass, and marrow adiposity seen with dietary energy restriction. J Appl Physiol. 1985;2012(113):1792–801.

    Google Scholar 

  7. Bonnet N, Pierroz DD, Ferrari SL. Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact. 2008;8:94–104.

    CAS  PubMed  Google Scholar 

  8. Togari A, Arai M. Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption. J Pharmacol Sci. 2008;106:542–6.

    Article  CAS  PubMed  Google Scholar 

  9. Pérez-Castrillón JL, De Luis DA, Duenas-Laita A. Are beta-blockers useful in the prevention of osteoporotic fractures? Eur Rev Med Pharmacol Sci. 2009;13:157–62.

    PubMed  Google Scholar 

  10. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC, Geelong Osteoporosis Study. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res. 2004;19:19–24.

    Article  CAS  PubMed  Google Scholar 

  11. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int. 2004;75:365–72.

    Article  CAS  PubMed  Google Scholar 

  12. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res. 2005;20:613–8.

    Article  CAS  PubMed  Google Scholar 

  13. Levasseur R, Dargent-Molina P, Sabatier JP, Marcelli C, Breart G. Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de L’Osteoporose Prospective Study. J Am Geriatr Soc. 2005;53:550–2.

    Article  PubMed  Google Scholar 

  14. Turker S, Karatosun V, Gunal I. Beta-blockers increase bone mineral density. Clin Orthop Relat Res. 2006;443:73–4.

    Article  PubMed  Google Scholar 

  15. Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone. 2007;40:1209–16.

    Article  CAS  PubMed  Google Scholar 

  16. Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Mendo M, Porrero MG, Dueñas A. Effect of beta-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine. 2007;74:259–62.

    Article  PubMed  Google Scholar 

  17. Yang S, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011;48:451–5.

    Article  CAS  PubMed  Google Scholar 

  18. Sosa M, Saavedra P, Gómez de Tejada MJ, Mosquera J, Pérez-Cano R, Olmos JM, Muñoz-Torres M, Amérigo MJ, Moro MJ, Díaz-Curiel M, Alegre J, Malouf J, Del Pino J, Nogués X, Torrijos A, GIUMO Cooperative Group. Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary heart disease. Aging Clin Exp Res. 2011;23:112–7.

    CAS  PubMed  Google Scholar 

  19. Bleicher K, Cumming RG, Naganathan V, Seibel MJ, Blyth FM, Le Couteur DG, Handelsman DJ, Creasey HM, Waite LM. Predictors of the rate of BMD loss in older men: findings from the CHAMP study. Osteoporos Int. 2013;24:1951–63.

    Article  CAS  PubMed  Google Scholar 

  20. Ağaçayak KS, Güven S, Koparal M, Güneş N, Atalay Y, Atılgan S. Long-term effects of antihypertensive medications on bone mineral density in men older than 55 years. Clin Interv Aging. 2014;9:509–13.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Reid IR, Lucas J, Wattie D, Horne A, Bolland M, Gamble GD, Davidson JS, Grey AB. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90:5212–6.

    Article  CAS  PubMed  Google Scholar 

  22. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case–control study. J Hypertens. 2006;24:581–9.

    Article  CAS  PubMed  Google Scholar 

  23. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA. 2004;292:1326–32.

    Article  CAS  PubMed  Google Scholar 

  24. Wiens M, Etminan M, Gill SS, Takkouche B. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med. 2006;260:350–62.

    Article  CAS  PubMed  Google Scholar 

  25. de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int. 2007;80:69–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2007;16:612–9.

    Article  PubMed  Google Scholar 

  27. Yang S, Nguyen ND, Eisman JA, Nguyen TV. Association between beta-blockers and fracture risk: a Bayesian meta-analysis. Bone. 2012;51:969–74.

    Article  CAS  PubMed  Google Scholar 

  28. Toulis KA, Hemming K, Stergianos S, Nirantharakumar K, Bilezikian JP. b-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects. Osteoporos Int. 2014;25:121–9.

    Article  CAS  PubMed  Google Scholar 

  29. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29:517–22.

    Article  PubMed  Google Scholar 

  30. Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med. 2012;172:1739–44.

    Article  PubMed  Google Scholar 

  31. Jensen J, Nielsen LH, Lyhne N, Hallas J, Brosen K. Drugs and femoral neck fracture: a case control study. J Intern Med. 1991;229:29–33.

    Article  CAS  PubMed  Google Scholar 

  32. Thorell K, Ranstad K, Midlöv P, Borgquist L, Halling A. Is use of fall risk-increasing drugs in an elderly population associated with an increased risk of hip fracture, after adjustment for multimorbidity level: a cohort study. BMC Geriatr. 2014;4(14):131.

    Article  Google Scholar 

  33. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006;166:241–46.

    Article  CAS  PubMed  Google Scholar 

  34. Meisinger C, Heier M, Lang O, Döring A. Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int. 2007;18:1189–95.

    Article  CAS  PubMed  Google Scholar 

  35. Solomon DH, Mogun H, Garneau K, Fischer MA. Risk of fractures in older adults using antihypertensive medications. J Bone Miner Res. 2011;26:1561–67.

    Article  CAS  PubMed  Google Scholar 

  36. Song HJ, Lee J, Kim YJ, Jung SY, Kim HJ, Choi NK, Park BJ. β1 selectivity of β-blockers and reduced risk of fractures in elderly hypertension patients. Bone. 2012;51:1008–15.

    Article  CAS  PubMed  Google Scholar 

  37. Shuto H, Imakyure O, Matsumoto J, Egawa T, Jiang Y, Hirakawa M, Kataoka Y, Yanagawa T. Medication use as a risk factor for inpatient falls in an acute care hospital: a case-crossover study. Br J Clin Pharmacol. 2010;69:535–42.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Järvinen TL, Sievänen H, Khan KM, Heinonen A, Kannus P. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008;336:124–6.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Ham AC, Swart KM, Enneman AW, van Dijk SC, Oliai Araghi S, van Wijngaarden JP, van der Zwaluw NL, Brouwer-Brolsma EM, Dhonukshe-Rutten RA, van Schoor NM, van der Cammen TJ, Lips P, de Groot LC, Uitterlinden AG, Witkamp RF, Stricker BH, van der Velde N. Medication-related fall incidents in an older, ambulant population: the B-PROOF study. Drugs Aging. 2014;31:917–27.

    Article  CAS  PubMed  Google Scholar 

  40. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;23(169):1952–60.

    Article  Google Scholar 

  41. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs. J Am Geriatr Soc. 1999;47:40–50.

    Article  CAS  PubMed  Google Scholar 

  42. Zang G. Antihypertensive drugs and the risk of fall injuries: a systematic review and meta-analysis. J Int Med Res. 2013;41:1408–17.

    Article  CAS  PubMed  Google Scholar 

  43. Gribbin J, Hubbard R, Gladman JR, Smith C, Lewis S. Risk of falls associated with antihypertensive medication: population-based case–control study. Age Ageing. 2010;39:592–7.

    Article  PubMed  Google Scholar 

  44. Imai S, Matsusue Y. Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc Res Tech. 2002;58:61–9.

    Article  CAS  PubMed  Google Scholar 

  45. Minkowitz B, Boskey AL, Lane JM, Pearlman HS, Vigorita VJ. Effects of propranolol on bone metabolism in the rat. J Orthop Res. 1991;9:869–75.

    Article  CAS  PubMed  Google Scholar 

  46. Rodrigues WF, Madeira MF, da Silva TA, Clemente-Napimoga JT, Miguel CB, Dias-da-Silva VJ, Barbosa-Neto O, Lopes AH, Napimoga MH. Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation. Br J Pharmacol. 2012;165:2140–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Zhang X, Lv X, Zhang Y, Jiao X, Chen B. Propranolol prevents osteoporosis and up-regulates leptin in ovariectomized rats. Iran J Pharm Res. 2013;12:557–62.

    PubMed Central  CAS  PubMed  Google Scholar 

  48. Sandhu HS, Herskovits MS, Singh IJ. Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec. 1987;219:32–8.

    Article  CAS  PubMed  Google Scholar 

  49. Cherruau M, Facchinetti P, Baroukh B, Saffar JL. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone. 1999;25:545–51.

    Article  CAS  PubMed  Google Scholar 

  50. Pasco JA, Henry MJ, Nicholson GC, Schneider HG, Kotowicz MA. Beta-blockers reduce bone resorption marker in early postmenopausal women. Ann Hum Biol. 2005;32:738–45.

    Article  PubMed  Google Scholar 

  51. Lind L, Hänni A, Hvarfner A, Pollare T, Ljunghall S, Lithell H. Influences of different antihypertensive treatments on indices of systemic mineral metabolism. Am J Hypertens. 1994;7:302–7.

    Article  CAS  PubMed  Google Scholar 

  52. Veldhuis-Vlug AG, Tanck MW, Limonard EJ, Endert E, Heijboer AC, Lips P, Fliers E, Bisschop PH. The effects of beta-2 adrenergic agonist and antagonist on human bone metabolism: a randomized controlled trial. Bone. 2015;71:196–200.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bone Metabolism Unit, Department of Internal Medicine, Hospital Marqués de Valdecilla, University of Cantabria-IDIVAL, Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Avda. Valdecilla s/n, 39008, Santander, Spain

    José L. Hernández & Carmen Valero

Authors
  1. José L. Hernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carmen Valero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José L. Hernández.

Ethics declarations

Conflict of interest

José L. Hernández and Carmen Valero declare that they have no any conflict of interest regarding this paper.

Animal/Human studies

The article does not contain any studies with human or animal subjects performed by the any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hernández, J.L., Valero, C. Effect of Beta-Blockers on Bone Mineral Density, Bone Turnover Markers and Fractures: A Clinical Review. Clinic Rev Bone Miner Metab 13, 185–193 (2015). https://doi.org/10.1007/s12018-015-9186-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12018-015-9186-9

Keywords

Search

Navigation